Assessing the bleeding risk in patients taking Dabigatran for catheter ablation by using eligibility criteria for large clinical trial of Dabigatran (3<sup>rd</sup> Report)

○Yasuyuki Takashima

[27P2-pm1-129] Assessing the bleeding risk in patients taking Dabigatran for catheter ablation by using eligibility criteria for large clinical trial of Dabigatran (3^rd Report)

○Yasuyuki Takashima^1,2, Shota Ichimizu^2,3, Kosuke Doki^1,3, Masato Homma^1,3 (1. Dept. of Pharm. Sci., Graduate School of Comprehensive Human Sciences, Univ. of Tsukuba, 2. T-CReDO, 3. Dept. of Pharm., Univ. of Tsukuba Hosp.)

Enter the password to view the abstracts.
The password will be emailed to those who have completed the registration.

Presentation information

[27P2-pm1] Clinical Pharmacy 2

[27P2-pm1-129] Assessing the bleeding risk in patients taking Dabigatran for catheter ablation by using eligibility criteria for large clinical trial of Dabigatran (3^rd Report)

Password

Presentation information

[27P2-pm1] Clinical Pharmacy 2

[27P2-pm1-129] Assessing the bleeding risk in patients taking Dabigatran for catheter ablation by using eligibility criteria for large clinical trial of Dabigatran (3rd Report)

Password

[27P2-pm1-129] Assessing the bleeding risk in patients taking Dabigatran for catheter ablation by using eligibility criteria for large clinical trial of Dabigatran (3^rd Report)